{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"85.5","value":"260"},{"groupId":"OG001","spread":"161","value":"404"},{"groupId":"OG002","spread":"481","value":"721"},{"groupId":"OG003","spread":"748","value":"1088"},{"groupId":"OG004","spread":"1040","value":"2374"},{"groupId":"OG005","spread":"3093","value":"3416"},{"groupId":"OG006","spread":"688","value":"3619"},{"groupId":"OG007","spread":"1332","value":"3798"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"284","value":"398"},{"groupId":"OG001","spread":"2566","value":"1971"},{"groupId":"OG002","spread":"686","value":"864"},{"groupId":"OG003","spread":"799","value":"1416"},{"groupId":"OG004","spread":"655","value":"2573"},{"groupId":"OG005","spread":"2738","value":"3776"},{"groupId":"OG006","spread":"1021","value":"4293"},{"groupId":"OG007","spread":"1733","value":"3178"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.7","value":"298"},{"groupId":"OG001","spread":"192","value":"542"},{"groupId":"OG002","spread":"475","value":"856"},{"groupId":"OG003","spread":"1102","value":"1560"},{"groupId":"OG004","spread":"1257","value":"2829"},{"groupId":"OG005","spread":"4460","value":"4383"},{"groupId":"OG006","spread":"1308","value":"4185"},{"groupId":"OG007","spread":"1805","value":"4543"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"title":"total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"283","value":"447"},{"groupId":"OG001","spread":"4034","value":"2906"},{"groupId":"OG002","spread":"1025","value":"1275"},{"groupId":"OG003","spread":"983","value":"2422"},{"groupId":"OG004","spread":"888","value":"3142"},{"groupId":"OG005","spread":"3334","value":"4798"},{"groupId":"OG006","spread":"1027","value":"5059"},{"groupId":"OG007","spread":"1913","value":"3834"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"39"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG003","spread":"NA","value":"0.102"},{"groupId":"OG004","spread":"0.0208","value":"0.0372"},{"groupId":"OG005","spread":"0.0454","value":"0.0570"},{"groupId":"OG006","spread":"0.0381","value":"0.0479"},{"groupId":"OG007","spread":"0.0333","value":"0.0468"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"16"}],"units":"Participants"}],"title":"SG3199: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"0.0152","value":"0.0704"},{"groupId":"OG004","spread":"0.0116","value":"0.0403"},{"groupId":"OG005","spread":"0.0449","value":"0.0485"},{"groupId":"OG006","spread":"0.00329","value":"0.0293"},{"groupId":"OG007","spread":"0.0325","value":"0.0516"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"description":"Cmax for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Maximum Observed Serum Concentration (Cmax) for ADCT-402","type":"SECONDARY","unitOfMeasure":"ng/mL"}